Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696956 | 1.00 | HRH3 (0.40) | HRH3MCHR1LSSPIK3CAPRKDC | |
| SCHEMBL14446159 | 0.87 | HRH3 (0.39) | HRH3MCHR1LSSPIK3CAPRKDC | |
| SCHEMBL14446163 | 0.86 | HRH3 (0.40) | HRH3MCHR1LSSADORA2AADORA2B | |
| SCHEMBL14446175 | 0.84 | HRH3 (0.39) | HRH3MCHR1LSSADORA2AADORA2B | |
| SCHEMBL14446172 | 0.83 | HRH3 (0.38) | HRH3MCHR1ADORA2AADORA2BGRM2 | |
| SCHEMBL1728688 | 0.82 | LSS (0.48) | HRH3MCHR1LSSPIK3CAPRKDC | |
| SCHEMBL1729124 | 0.81 | LSS (0.47) | HRH3MCHR1LSSPIK3CAPRKDC | |
| SCHEMBL1729760 | 0.81 | LSS (0.47) | HRH3MCHR1LSSPIK3CAPRKDC | |
| SCHEMBL14446169 | 0.79 | HRH3 (0.38) | HRH3MCHR1ADORA2AADORA2BGRM2 | |
| SCHEMBL4697494 | 0.79 | HRH3 (0.43) | HRH3EPHX2ADORA2AADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711473-B1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | HRH3 3058/4885MCHR1 3539/4885LSS 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.